Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

Authors :: Niven Mehra
Antoine G. van der Heijden
Mark A.J. Gorris
Harm Westdorp
Jack A. Schalken
Marjolijn J. L. Ligtenberg
Katrien Grünberg
Tjitske Duiveman-de Boer
Jennifer Jones
Jolanda De Vries
Kiek Verrijp
James L. Gulley
Inge M. van Oort
Alfred Witjes
Winald R. Gerritsen
Thomas J. Van Ee
Minke Smits
Astrid Eijkelenboom
Michiel Sedelaar
Johannes Textor
Source :: Journal of Clinical Oncology. 36:5036-5036
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 5036Background: Predictive biomarkers are needed to improve the proportion of pts with mCRPC that may benefit from anti-PD-1/PD-L1 ICB. A comprehensive characterization of both genomic alterations ...

Subjects :: Cancer Research
business.industry
Anti pd 1
Castration resistant
medicine.disease
Immune checkpoint
Blockade
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
medicine
Cancer research
DNA mismatch repair
business
030215 immunology
Predictive biomarker

Full Text Access

Tools